

**South Dakota Department of Social Services, Division of Medicaid Services  
Pharmacy & Therapeutics (P&T) Committee Meeting Minutes**

Friday, September 18, 2020

1:00 – 3:00 pm CT

**Members and DSS Staff**

Michelle Baack, MD	-	Heather Preuss, MD	X
Dana Darger, RPh, Chair	X	Matthew Stanley, DO	X
Mikal Holland, MD	X	Deidre Van Gilder, PharmD	X
Bill Ladwig, RPh	X	Mike Jockheck, DSS Staff	X
Kelley Oehlke, PharmD	X	Bill Snyder, DSS Staff	X
Lenny Petrik, PharmD	X		

**Administrative Business**

Darger called the meeting to order at 1:14 PM. The minutes of the June meeting were presented. Holland made a motion to approve. Oehlke seconded the motion. The motion was unanimously approved via roll call vote.

Snyder updated the committee on DSS staff. Sarah Akers left DSS. Matthew Ballard is the new Deputy Division Director of Medical Services. In addition, the hepatitis C criteria will be expanding to F2 score effective 1/1/2021.

**Prior Authorization Update (PA) and Statistics**

The committee reviewed the PA activity report from April 1, 2020 to June 30, 2020. A total of 1,358 PAs were reviewed of which 147 requests (11%) were received via telephone and 807 requests (59%) were received via fax, and 404 (30%) were reviewed via electronically. This was a 23% decrease of PAs received from the previous quarter.

**Analysis of the Top 15 Therapeutic Classes and Drug Spend**

The committee reviewed the top 15 therapeutic classes by total cost of claims from April 1, 2020 to June 30, 2020. The top five therapeutic classes based on paid amount were atypical antipsychotics, disease-modifying anti-rheumatic agents, amphetamines, anticonvulsants, and cystic fibrosis correctors. The top 15 therapeutic classes make up 24.88% of total claims. The committee also reviewed the top 50 drugs based on amount paid and number of claims. The top 50 drugs by amount paid make up 10.8% of total claims. New utilization for Upravi was noted on the top 50 drugs based on amount paid.

**Old Business**

**CGRP & Orilissa utilization**

The committee reviewed the calcitonin gene related peptide (CGRP) and triptan utilization comparing 1Q20 through 2Q20. The committee also reviewed utilization of Orilissa and Oriahnn comparing 1Q20 through 2Q20. Committee commented observing appropriate utilization. Committee decided to not monitor quarterly but if spikes in utilization occur to bring them back for further review. Ladwig was satisfied with number of members utilizing Epidiolex.

### **Atypical antipsychotic utilization in children**

Committee reviewed atypical antipsychotic utilization in children 17 years old and under. As part of the review, Stanley had spoken to hospitalists in child and adolescent specialties as reference points since these physicians see many children with the majority being critical cases. They commented regarding the 17% of children taking multiple products. Stanley also provided insight on treatment for autistic spectrum disorder and dementia where there is not a standard approach that works every time. Jockheck suggested eliminating the two drug criteria and have the option of using two drugs through an appeal process in the PA criteria. Stanley inquired of the 17% utilizers how many were seen by psychiatrists? He requested diagnosis information for the next meeting. In addition, the use of ADHD medications was also briefly discussed. Darger and Stanley will review how other Medicaid states are handling criteria.

### **Review of Reyvow & Ubrelvy fax form**

Ladwig made a motion to table this review until the next meeting. Stanley seconded the motion. Roll call vote was passed unanimously.

### **Opioid update**

The committee reviewed 2Q20 opioid outcomes compared to previous quarters from the opioid initiatives. Utilization trends downward. Ladwig inquired for poly pharmacy information if pharmacy counted as each pharmacy or each chain. Jockheck confirmed for each pharmacy.

### **New Committee Member**

Darger warmly welcomed new committee member, Dr. Heather Preuss, a provider in Hot Springs. Jockheck also expressed his thanks and welcomed Dr. Preuss. Preuss expressed her wish to observe and learn.

### **New Business**

#### **Humira CF utilization**

Darger had requested to compare Humira and Humira citrate free (CF) at the last meeting. Jockheck confirmed favorable savings for Humira compared to the new formulation of Humira CF. Darger expressed there is no difference in therapy except Humira CF doesn't sting as bad as the citrate version. Committee discussed using Humira citrate version before allowing Humira CF. Jenna Gianninoto from AbbVie was available for any questions from the committee. Ladwig motioned to bring proposed PA criteria to the next meeting. Holland seconded the motion. The motion was unanimously approved via roll call vote.

#### **Nurtec ODT**

Nurtec ODT clinical information was presented for review. Chelsea Leroue from Biohaven provided public comment on Nurtec ODT. Committee discussed adding Nurtec ODT to the current PA for Reyvow and Ubrelvy. Oehlke made the motion and Van Gilder seconded the motion. The motion was unanimously approved via roll call vote.

#### **Palforzia**

Palforzia clinical information was presented for review. Shannon Payne from Aimmune provided public comment on Palforzia. Darger reiterated the stringent REMS on Palforzia. Holland recommended monitoring it.

**Nayzilam & Valtoco**

Clinical information on Nayzilam and Valtoco were presented for review. Cindy Hartford from Neuretis provided public comment on Valtoco. Preuss cited main concern would be abuse potential. Stanley inquired about the number of doses in each nasal spray. Hartford replied a single dose in each nasal spray. Ladwig suggested watching utilization. Utilization data will be provided for Nayzilam, Valtoco and the diazepam rectal gels.

**Adjournment**

Snyder inquired about using zoom or another video conference call application for the next meeting. Darger expressed his favor and committee agreed. The next meeting is scheduled for December 11, 2020. The March meeting is tentatively scheduled on March 5, 2021. Ladwig made a motion to adjourn the meeting and Preuss seconded the motion. The motion passed unanimously by everyone leaving, and the meeting adjourned 2:35 PM.

DRAFT